Bio-Path (BPTH) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 02, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	BIO-PATH HOLDINGS INC
Entity Central Index Key	1,133,818
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	BPTH
Entity Common Stock, Shares Outstanding		95,645,224

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash	$ 11,299	$ 8,854
Prepaid drug product for testing	196	560
Other current assets	912	179
Total current assets	12,407	9,593
Fixed assets
Furniture, fixtures & equipment	148	123
Less accumulated depreciation	(82)	(51)
Property, Plant and Equipment, Net	66	72
Other assets
Technology licenses	2,500	2,500
Less accumulated amortization	(1,531)	(1,410)
Intangible Assets, Net (Excluding Goodwill), Total	969	1,090
Total Assets	13,442	10,755
Current liabilities
Accounts payable	118	54
Accrued expense	748	883
Total current liabilities	866	937
Warrant liability	3,199	0
Total Liabilities	4,065	937
Shareholders’ equity
Preferred stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.001 par value, 200,000,000 shares authorized 95,645,224 and 89,762,872 shares issued and outstanding as of 9/30/16 and 12/31/15, respectively	96	90
Additional paid in capital	40,044	35,112
Accumulated deficit	(30,763)	(25,384)
Total shareholders’ equity	9,377	9,818
Total Liabilities & Shareholders’ Equity	$ 13,442	$ 10,755

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	95,645,224	89,762,872
Common Stock, shares outstanding	95,645,224	89,762,872

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses
Research and development	2,313	992	4,520	2,149
General and administrative	681	520	2,287	1,873
Total operating expenses	2,994	1,512	6,807	4,022
Net operating loss	(2,994)	(1,512)	(6,807)	(4,022)
Other income
Change in fair value of warrant liability	1,420	0	1,420	0
Interest income	4	4	8	14
Total other income	1,424	4	1,428	14
Net loss	$ (1,570)	$ (1,508)	$ (5,379)	$ (4,008)
Net loss per share, basic and diluted	$ (0.02)	$ (0.02)	$ (0.06)	$ (0.04)
Basic and diluted weighted average number of common shares outstanding	95,645	89,763	91,724	89,763

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flow from operating activities
Net loss	$ (5,379)	$ (4,008)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	121	121
Depreciation	31	31
Stock-based compensation	550	283
Change in fair value of warrant liability	(1,420)	0
(Increase) decrease in assets
Prepaid drug product for testing	364	(250)
Other current assets	(733)	(100)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(71)	(81)
Net cash used in operating activities	(6,537)	(4,004)
Cash flow from investing activities
Purchase furniture, fixtures & equipment	(25)	0
Net cash used in investing activities	(25)	0
Cash flow from financing activities
Net proceeds from sale of common stock	9,007	0
Net cash provided by financing activities	9,007	0
Net increase (decrease) in cash	2,445	(4,004)
Cash, beginning of period	8,854	13,859
Cash, end of period	$ 11,299	$ 9,855

Organization and Business

Organization and Business	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business The Company is a clinical and preclinical stage oncology focused antisense drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology, called DNAbilize™, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The Company believes this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize™ delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize™ as a platform for drug development and manufacturing, we currently have two antisense drug candidates in development to treat a total of five different disease indications. Our lead drug candidate, Liposomal Grb2 (“BP1001”), targets the protein Grb2 and has entered the efficacy portion of a Phase II clinical trial for acute myeloid leukemia (AML) and is preparing to enter the safety segment of a Phase II clinical trial for blast phase and accelerated phase chronic myelogenous leukemia (CML). BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. The Company’s second drug candidate, Liposomal Bcl2 (“BP1002”), targets the protein Bcl2, which is responsible for driving cell proliferation in up to 60% of all cancers. BP1002 is in preparation for an Investigational New Drug application. Bio-Path Subsidiary was founded in May 2007 as a Utah corporation. In February 2008, Bio-Path Subsidiary completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates. 25.0 On June 29, 2016, the Company entered into the Securities Purchase Agreement with certain healthcare focused institutional investors pursuant to which the Company agreed to sell an aggregate of 5,882,352 2,941,176 10.0 9.3 0.3 As of September 30, 2016, Bio-Path had $11.3 million in cash on hand. As the Company has not begun its planned principal operations of commercializing a product candidate, the Company’s activities are subject to significant risks and uncertainties, including the potential requirement to secure additional funding, the outcome of the Company’s clinical trials, and failing to operationalize the Company’s current drug candidates before another company develops similar products.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Stock Compensation. Management has reviewed all other recently issued pronouncements and has determined they will have no material impact on the Company’s consolidated financial statements.

Prepaid Drug Product for Testin

Prepaid Drug Product for Testing	9 Months Ended
	Sep. 30, 2016
Prepaid Drug Product For Testing [Abstract]
Prepaid Drug Product for Testing	Prepaid Drug Product for Testing Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future clinical development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company incurred installments to its contract drug manufacturing and raw material suppliers totaling $ 0.6 0.2

Other Current Assets

Other Current Assets	9 Months Ended
	Sep. 30, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets As of September 30, 2016, Other Current Assets included prepaid expenses of $0.9 million, comprised primarily of prepayments made to the Company’s clinical research organization for our Phase II clinical trial for BP1001 in AML. As of December 31, 2015, Other Current Assets included prepaid expenses of $0.2 million.

Accounts Payable

Accounts Payable	9 Months Ended
	Sep. 30, 2016
Accounts Payable Disclosure [Abstract]
Accounts Payable	5. Accounts Payable As of September 30, 2016, Current Liabilities included accounts payable of $ 0.1 0.1

Accrued Expense

Accrued Expense	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities [Abstract]
Accrued Expense	Accrued Expense 0.7

Warrant Liability

Warrant Liability	9 Months Ended
	Sep. 30, 2016
Derivative Liability [Abstract]
Warrant Liability Disclosure [Text Block]	7. Warrant Liability In connection with the 2016 Registered Direct Offering, the Company issued warrants to purchase up to 2,941,176 250,000 Due to this provision and in accordance with ASC 480-10 (FASB Statement 150, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity), the 2016 Warrants were classified as a liability and recorded at fair value using the Binomial Lattice Model. The estimated fair value of the Warrant Liability for the 2016 Warrants on the closing date, July 5, 2016, was $ 4.6 3.2 1.4

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Fair Value Measurements In accordance with ASC 820, the Company uses various inputs to measure the 2016 Warrants on a recurring basis to determine the fair value of the liability. ASC 820 also establishes a hierarchy categorizing inputs into three levels used to measure and disclose fair value. The hierarchy gives the highest priority to quoted prices available in active markets and the lowest priority to unobservable inputs. An explanation of each level in the hierarchy is described below: Level 1 – Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement date Level 2 – Quoted prices in markets that are not active or inputs which are either directly or indirectly observable Level 3 – Unobservable inputs for the instrument requiring the development of assumptions by the Company Fair Value Measurements at September 30, 2016 (in thousands) Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ - $ - $ 3,199 $ 3,199 The Company did not have the 2016 Warrants at December 31, 2015. Fair Value of Warrant Liability (in thousands) Balance at December 31, 2015 $ - Issuance 4,619 Change in fair value (1,420) Balance at September 30, 2016 $ 3,199 As of 2016 Risk-free interest rate 1.14 % Expected volatility 104 % Expected term in years 5.3 Dividend yield - %

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Stockholders’ Equity totaled $ 9.4 9.8 95,645,224

Stock-Based Compensation and Wa

Stock-Based Compensation and Warrants	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation and Warrants	10. Stock-Based Compensation and Warrants The Plan - In 2007, the Company adopted the First Amended 2007 Stock Incentive Plan, as amended (the “Plan”). The Plan provides for the grant of Incentive Stock Options, Nonqualified Stock Options, Restricted Stock Awards, Restricted Stock Unit Awards, Performance Awards and other stock-based awards, or any combination of the foregoing to the Company’s key employees, non-employee directors and consultants. Under the Plan, the exercise price is determined by the Board of Directors or the compensation committee of the Board of Directors, and for options intended to qualify as qualified incentive stock options, may not be less than the fair market value as determined by the closing stock price at the date of the grant. Each option and award shall vest and expire as determined by the Board of Directors or the compensation committee. Options expire no later than ten years from the date of grant. All grants provide for accelerated vesting if there is a change of control, as defined in the Plan. Stock-based compensation expense was $ 0.2 0.1 0.1 0.1 36,000 Stock-based compensation expense was $ 0.6 0.3 0.3 0.2 0.2 0.1 2016 2015 Risk-free interest rate 1.37 % 1.65 % Expected volatility 109 % 138 % Expected term in years 6.1 6.1 Dividend yield - % - % Weighted Average Exercise Options Price (in thousands) Outstanding at December 31, 2015 5,752 $ 1.05 Granted 1,300 2.55 Outstanding at September 30, 2016 7,052 1.33 Exercisable at September 30, 2016 5,420 $ 1.00 As of September 30, 2016, the aggregate intrinsic value of outstanding stock options was $ 2.4 2.0 As of September 30, 2016, unamortized stock-based compensation expense for all outstanding options was $ 2.1 3.1 W arrants - 10,000 0.90

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Technology License – 0.1 Operating Leases – 0.2 In April 2016, the Company entered into a three-year lease agreement for lab space located in Bellaire, Texas. The term of lease began on May 1, 2016 and terminates on April 30, 2019 and will require Bio-Path to pay $ 2,500 0.1 Drug Supplier Project Plan – 0.1 0.1 0.9 0.1 0.2 . Service Agreement – On September 30, 2016, the Company entered into a service agreement with a preclinical stage biotechnology company in connection with a development project involving our DNAbilize™ technology, pursuant to which we agreed to perform certain evaluation services in exchange for $ 50,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table summarizes the Company’s 2016 Warrants measured at fair value within the hierarchy on a recurring basis as of September 30, 2016: Fair Value Measurements at September 30, 2016 (in thousands) Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ - $ - $ 3,199 $ 3,199
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table summarizes changes to the fair value of the Level 3 2016 Warrants for the nine months ended September 30, 2016: Fair Value of Warrant Liability (in thousands) Balance at December 31, 2015 $ - Issuance 4,619 Change in fair value (1,420) Balance at September 30, 2016 $ 3,199
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The Company utilized the Binomial Lattice Model for estimating the fair value of the 2016 Warrants using the following assumptions as of September 30, 2016: As of 2016 Risk-free interest rate 1.14 % Expected volatility 104 % Expected term in years 5.3 Dividend yield - %

Stock-Based Compensation and 18

Stock-Based Compensation and Warrants (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock options granted, with 2016 2015 Risk-free interest rate 1.37 % 1.65 % Expected volatility 109 % 138 % Expected term in years 6.1 6.1 Dividend yield - % - %
Schedule of Share-based Compensation, Stock Options, Activity	The following summary represents option activity under the Company’s stock-based compensation plan for the nine months ended September 30, 2016: Weighted Average Exercise Options Price (in thousands) Outstanding at December 31, 2015 5,752 $ 1.05 Granted 1,300 2.55 Outstanding at September 30, 2016 7,052 1.33 Exercisable at September 30, 2016 5,420 $ 1.00

Organization and Business - Add

Organization and Business - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 29, 2016	Jun. 30, 2015	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Organization and Nature of Operations [Line Items]
Cash			$ 11,299	$ 8,854	$ 9,855	$ 13,859
Stock issued during period, shares, new issues	5,882,352
Stock issued during period, value, new issues	$ 10,000
Proceeds from issuance initial public offering	9,300
Debt Issuance Costs, Net	$ 300
Common Stock
Organization and Nature of Operations [Line Items]
Stock To Be Issued		25,000,000
Warrant
Organization and Nature of Operations [Line Items]
Stock issued during period, shares, new issues	2,941,176

Prepaid Drug Product for Test20

Prepaid Drug Product for Testing - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Prepaid Expenses Disclosure [Line Items]
Prepaid drug product for testing	$ 196	$ 560

Other Current Assets - Addition

Other Current Assets - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Other Assets Current	$ 912	$ 179
Prepaid Expenses [Member]
Other Assets Current		$ 200

Accounts Payable - Additional I

Accounts Payable - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Accounts Payable [Line Items]
Accounts payable	$ 0.1	$ 0.1

Accrued Expense - Additional In

Accrued Expense - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense	$ 748	$ 883

Warrant Liability - Additional

Warrant Liability - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Jul. 05, 2016
Warrant Liability [Line Items]
Derivative Liability, Fair Value, Gross Liability	$ 3.2	$ 4.6
Increase (Decrease) in Derivative Liabilities	$ 1.4
Healthcare Institutional Investors [Member]
Warrant Liability [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,941,176
H.C. Wainwright Co., LLC [Member]
Warrant Liability [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	250,000

Fair Value, Assets and Liabilit

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 3,199	$ 0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 3,199

Fair Value Of Warrant Liability

Fair Value Of Warrant Liability (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at December 31, 2015	$ 0
Issuance	4,619
Change in fair value	(1,420)
Balance at September 30, 2016	$ 3,199

Fair Value Assumptions and Meth

Fair Value Assumptions and Methodology for Assets and Liabilities (Detail)	9 Months Ended
	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Risk-free interest rate	1.14%
Expected volatility	104.00%
Expected term in years	5 years 3 months 18 days
Dividend yield	0.00%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Shareholders Equity [Line Items]
Common Stock, shares issued	95,645,224	89,762,872
Common Stock, shares outstanding	95,645,224	89,762,872
Stockholders Equity	$ 9,377	$ 9,818

Weighted Average Assumptions (D

Weighted Average Assumptions (Detail)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Plans [Line Items]
Risk-free interest rate	1.37%	1.65%
Expected volatility	109.00%	138.00%
Expected term in years	6 years 1 month 6 days	6 years 1 month 6 days
Dividend yield	0.00%	0.00%

Option Activity Under Plan (Det

Option Activity Under Plan (Detail) shares in Thousands	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Share Based Compensation Plans [Line Items]
Outstanding | shares	5,752
Granted | shares	1,300
Outstanding | shares	7,052
Exercisable | shares	5,420
Weighted - Average Exercise Price, Outstanding | $ / shares	$ 1.05
Weighted - Average Exercise Price, Granted | $ / shares	2.55
Weighted - Average Exercise Price, Outstanding | $ / shares	1.33
Weighted - Average Exercise Price, Exercisable | $ / shares	$ 1

Stock-Based Compensation and 31

Stock-Based Compensation and Warrants - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Stock Based Compensation Plans [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 2,100,000		$ 2,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			2,400,000		$ 2,000,000
Stock-based compensation expense	$ 200,000	$ 100,000	$ 600,000	$ 300,000
Stock Compensation Plan [Member]
Stock Based Compensation Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term			3 years 1 month 6 days
Warrants
Stock Based Compensation Plans [Line Items]
Class of Warrant or Right, Outstanding	10,000		10,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.90		$ 0.90
Research and Development Expense
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense	$ 100,000	$ 36,000	$ 200,000	100,000
General and Administrative Expense [Member]
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense	$ 100,000		$ 300,000	$ 200,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Apr. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Product Liability Contingency [Line Items]
Accounts payable and accrued liabilities			$ 100,000
Drug Product Testing Agreement Consideration To Be Paid In Stages		$ 100,000
Prepaid Expense, Current		196,000	$ 560,000
Drug Supplier Commitments Development		200,000
Development Project ,Service Evaluation Exchange Cost		50,000
Lab Space [Member]
Product Liability Contingency [Line Items]
Operating Leases, Future Minimum Payments Due		100,000
Operating Lease Monthly Rental Payments	$ 2,500
Office Space [Member]
Product Liability Contingency [Line Items]
Operating Leases, Future Minimum Payments Due		200,000
Second Drug [Member]
Product Liability Contingency [Line Items]
Prepaid Expense, Current		100,000
Final Drug [Member]
Product Liability Contingency [Line Items]
Drug Product Testing Agreement Consideration To Be Paid In Stages		100,000
Drug Supplier Commitments Development		$ 900,000